Cancer clinical research centers

In the case of cancer, that is, advanced or metastasized cancer, a recommendation is that cancer clinical research centers, or CCRCs, be set up in new or existing facilities, as previously indicated. These would comprise a nationwide network, even worldwide, and would be staffed by M.D.s and D.O.s commonly supported by a variety of pharmacologists, botanists, herbalists, etc., who are familiar with the world of plants and plant medicines, the main source for alternatives. In a way, the Cancer Treatment Centers of America tend to fill this function at least partially, although there are only three locations, in the Chicago area, in Tulsa, and in Seattle. Both conventional and CAM therapies are offered, at the patient s discretion. It may be mentioned in passing that the CTCA no longer speaks of cures but of treatments, after they ran into trouble with the Federal Trade Commission (FTC) back in 1996. 

In the conrse of the work, the NCI decided on plans for nsing intermediate markers or indicators for the conrse of genetic, biochemical, and immnnologic fnnctions. This avoids the long waiting period for incipient cancers to grow. (Even more decisive wonld be a protocol of chnical tests for patients already snffering with cancer, for example, in cancer clinical research centers.)... 

For the reasons mentioned previously, in whole or in part, it is recommended that widespread and convenient cancer clinical research centers (CCRC) or their... 

We note that Dr. Horrobin s philosophy agrees with the concept of creating a countrywide network of cancer clinical research centers, or CCRCs, as previously noted. Dr. Horrobin was also cited in Part 2 of Marcus Cohen s articles on medical censorship.)... 

It is added by Dr. Nair that eight out of ten cancer patients now use some form of complementary and alternative medicine (CAM), mostly in conjunction with conventional medical treatments. (This, in comment, should supposedly lead to a significant decrease in cancer-related deaths.) Moreover, the use of Haelan 951 can apparently serve as an adjuvant in conjimction with conventional chemotherapy. Whereas thousands of patients in the United States, Europe, and Asia have been taking Haelan 951 as an adjunct or stand-alone treatment for cancer, most of the clinical trials have been conducted at medical and research institutions in China. More such clinical research is called for in the United States. (This is most likely, given the prevailing mind-set of the medical establishment. However, the creation of cancer clinical research centers [CCRCs] would fulfill this need, as described elsewhere.)... 

Lastly, the ultimate word is always that of clinical successes, and for this reason it is advocated that a network of cancer clinical research centers (CCRCs) be instituted — or the equivalent — to serve initially as a court of last resort for advanced or terminal cancer cases, and later on for any case. These would be primarily staffed by M.D.s and D.O.s, and backed by a system of supportive pharmacologists, biochemists, botanists and ethnobotanists, biologists and zoologists, plus assorted naturopaths and the like — even if considered unconventional, but which are possibly a vital link in the therapeutic chain. 

The HSV/A studies were supported by Grant No. POl CA66726 from the National Cancer Institute andGrantM01-RR00040 to the General Clinical Research Center of the University of Pennsylvania Medical Center from the National Gene Vector Laboratories, the Nicolette Asbestos Trust, the Benjamin Shein Foundation for Humanity, and the Samuel H.Lunenfeld Charitable Foundation. Institutional support was provided by the University of Pennsylvania Cancer Center. 

Antonia Dimitrakopoulou-Strauss Medical PET Group, Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany... 

Associate Director for Clinical Research Greenebaum Cancer Center University of Maryland Baltimore, MD 21201-1595... 

The research program at NIH also uses pharmacists in many of its 14 institutes. Pharmacists in the National Cancer Institute s (NCI s) Pharmaceutical Management Branch are involved in anticancer drug development, protocol development, collection of clinical data, distribution of NCI investigational drugs and the Treatment Referral Center. In addition, the intramural program of the NCI has a pharmacokinetics laboratory where pharmacists perform basic and clinical research. The National Institute of Allergy and Infectious Diseases (NIAID) Division of AIDS pharmacists participate in protocol development and implementation, and act as consultants to more than 300 pharmacists involved in NIAID-sponsored AIDS clinical trials. 

Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D5-390, Seattle, WA 98109-1024 Department of Medicine, University of Washington School of Medicine,... 

David Lohnes Clinical Research Institute of Montreal, Quebec, Canada Reuben Lot an Department of Tumor Biology, MD Anderson Cancer Center, University of Texas, Houston, TX Andrew D. Loughney Medical Molecular Biology Group, Medical School, University of Newcastle upon Tyne, UK Sally D. Lyn Department of Molecular Immunology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA... 

After toxicological studies in large animals, a Phase I study was started at the Lilly Laboratories for Clinical Research (6) with eight patients with a variety of cancers Subsequently, Phase I studies were conducted in several research centers, including ours (7, 8). These reports provide data on drug doses and schedules used, observed systemic toxicity (mainly mucocutaneous toxicity and myelosuppression), and reasons for discontinuation of PF treatment. Our recommended dose is 250 mg/m i,v. bolus, q 2-3 wk. Of the approximately 100 patients treated to-date, partial response was shown in patients with breast carcinoma (8) acute myelocytic leukemia (9) and Hodgkin s Diseases (5). 

Hydrazine sulfate [10034-93-2] N2H4 H2SO4, originally advanced by the Syracuse Cancer Research Institute for treatment of cancerous cachexia and tumor inhibition (221), now has Investigational New Dmg (IND) status in the United States. Clinical evaluations are under way at various institutions such as Harbor-UCLA Medical Center (222) and the Mayo Clinic. After extensive trials, hydrazine sulfate has been approved as an anticancer dmg in Russia (223). Chemical stmctures for estabUshed dmgs in the United States may be found in Reference 224. 

Clinical Pharmacology Program, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland... 

---